Initial Denosumab Versus Sequential Bisphosphonate-to-Denosumab for Prevention of Skeletal-Related Events in Breast Cancer with Bone Metastases: A Retrospective, Single-Center Study.

Cancers (Basel) · 2026 · PMC13115166 · PMID 42073549

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

did not reach statistical significancep = 0.068so close (0.05 < p ≤ 0.1)

Kaplan–Meier analysis of time to first on-treatment SRE showed a numerically lower risk in the initial denosumab group, although the between-group difference did not reach statistical significance (HR = 0.335, 95% CI 0.098–1.147; p = 0.068) ( Figure 3 ). 3.4.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.